Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab?
Pharmaceutical Technology
FEBRUARY 18, 2023
Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
100 
Let's personalize your content